Immunitybio, Inc.

This study tests a new combination of treatments for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The approach uses specially engineered immune cells (CD19 t-haNK) plus an immune booster (N-803) along with the stand…

This study tests a combination of drugs (nogapendekin alfa inbakicept, bevacizumab, and immune cells called PD-L1 t-haNK) with or without tumor treatment fields (a device that uses electric fields to disrupt cancer growth) in people whose glioblastoma has come back or worsened. T…

This program provides a genetically modified version of the standard BCG treatment to people with non-muscle invasive bladder cancer who are not able to join a clinical trial. It is for adults aged 18 and older with high-grade transitional cell carcinoma. The goal is to offer a p…

This study tests the safety of a drug called NAI (Anktiva) in 40 adults aged 18-70 with long COVID—symptoms that persist after a COVID-19 infection. Researchers will monitor side effects and changes in lab results and vital signs over 30 days after treatment. The goal is to see i…

This study tests whether a drug called Anktiva is safe and tolerable for people with Long COVID. About 20 adults who have had COVID-19 will receive up to two doses and be monitored for side effects and symptom changes. The goal is to see if this treatment can help reduce ongoing …